Study to Investigate the Influence of Hepatic Insufficiency on

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT05009680` - A Single and Repeat Dose Trial in Participants With Hepatic Impairment	Phase 1/Phase 2
Recruiting	`NCT04494269` - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls	Phase 1
Terminated	`NCT05517226` - Pharmacokinetics of Cotadutide in Participants With Hepatic Impairment	Phase 1
Completed	`NCT03983161` - A Pharmacokinetics and Tolerability Study of Fedratinib in Subjects With Moderate and Severe Hepatic Impairment	Phase 1
Completed	`NCT04546789` - Effect of Hepatic Impairment on M2951 (BTK Inhibitor) PK	Phase 1
Completed	`NCT03282513` - A Study of AG-120 (Ivosidenib) in Subjects With Mild or Moderate Hepatic Impairment or Normal Hepatic Function	Phase 1
Recruiting	`NCT05976321` - A Study of TAK-279 in Adults With or Without Liver Damage	Phase 1
Completed	`NCT04473664` - A Study of Quizartinib Pharmacokinetics in Participants With Moderate Hepatic Impairment	Phase 1
Recruiting	`NCT05484206` - Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434	Phase 1
Completed	`NCT03290443` - A Study to Assess the Pharmacokinetics of Enasidenib (CC-90007) in Subjects With Moderate and Severe Hepatic Impairment.	Phase 1
Completed	`NCT02245243` - Pharmacokinetics of Delafloxacin in Subjects With and Without Hepatic Impairment	Phase 1
Completed	`NCT02244827` - Pharmacokinetics of WCK 2349 In Patients With Hepatic Impairment	Phase 1
Completed	`NCT02004587` - Influence of Hepatic Impairment on Pharmacokinetic (PK) and Pharmacodynamic (PD) of Gemigliptin PK and PD After Multiple Oral Doses in Healthy White Volunteers	Phase 1
Completed	`NCT01621633` - A Study of LCZ696 in Subjects With Mild and Moderate Hepatic Impairment Compared With Normal Healthy Volunteers	Phase 2
Completed	`NCT01493869` - Study to Assess the Pharmacokinetics of Cabozantinib (XL184) in Hepatic Impaired Adult Subjects	Phase 1
Completed	`NCT04482270` - A Study to Investigate the Effect of Mild and Moderate Hepatic Impairment on the Safety and Tolerability of Fezolinetant Compared to Participants With Normal Hepatic Function	Phase 1
Completed	`NCT02115347` - Pharmacokinetics, Safety, and Tolerability of Ertugliflozin (MK-8835/PF-04971729) in Participants With Hepatic Impairment and in Healthy Participants (MK-8835-014)	Phase 1
Recruiting	`NCT04950764` - An Open-Label Study Following Oral Dosing of Seladelpar to Subjects With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)	Phase 1
Completed	`NCT06161259` - Pharmacokinetics of Leritrelvir(RAY1216) in Participants With Hepatic Impairment	Phase 1
Completed	`NCT05409911` - A Study to Assess S-217622 in Participants With Mild and Moderate Hepatic Impairment and Healthy Control Participants	Phase 1

NCT number	NCT03212313
Study type	Interventional
Source	Biotie Therapies Inc.
Contact
Status	Terminated
Phase	Phase 1
Start date	June 30, 2017
Completion date	December 31, 2017

Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Tozadenant

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms